MedTrace Logo

Belimumab Impacting Transplant Eligibility

NCT02500251 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-04-22

No results posted yet for this study

Summary

This study is a prospective, open label, phase I/II pilot study.

Conditions

  • Renal Transplant Rejection

Interventions

DRUG

belimumab

Belimumab will be administered per study protocol.

DRUG

Bortezomib

Bortezomib will be administered per study protocol.

DRUG

Rituximab

Rituximab will be administered per study protocol.

DRUG

Plasmapheresis

Plasmapheresis will be administered per study protocol.

Sponsors & Collaborators

Principal Investigators

  • E. Steve Woodle, MD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-06-30
Completion
2018-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02500251 on ClinicalTrials.gov